Sexual Health

PT-141

Half-life: 2.7h Subcutaneous injection into the abdomen or thigh, at least 45 minutes before anticipated activity.

Warnings. Can cause transient blood-pressure increases and nausea. Max 1 dose per 24h and 8 doses per month on the label; limit use in uncontrolled hypertension.

Mechanism

Melanocortin-4 receptor (MC4R) agonist acting on hypothalamic pathways to increase sexual arousal and desire.

Overview

PT-141 (Bremelanotide) is a melanocortin receptor agonist FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors it acts centrally on the nervous system to increase sexual desire rather than on blood flow. It is effective in both men and women.

Protocols

As-Needed Dosing

Official BEGINNER

On-demand use with strict weekly limits.

Goal: Libido and sexual function

Step 1 4w

1.5 mg · 1×/day · At least 45 minutes before activity

1-2mg as needed, maximum 2 doses per week (and never more than 1 dose per 24 hours). Start at 1mg to assess nausea.